Use of eribulin and Mtor inhibitors as combination therapy for the treatment of cancer

• Main Authors: FUNAHASHI YASUHIRO, LITTLEFIELD BRUCE A, UENAKA TOSHIMITSU
• Format: Patent
• Language: Chinese; English
• Published: 12.10.2016
• Subjects: HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES

Methods for treating cancer (e.g., breast cancer, lung cancer, pancreatic cancer, primitive neuroectodermal tumors, lung cancer, ovaria cancer, endometrial cancer, pharyngeal cancr, esophageal cancer, and sarcoma) in a subject (such as an human patient) in need thereof by administering eribulin (e.g., eribulin mesylate, i.e., E7389, Halaven) in combination with one or more mammalian target of rapamycin (mTOR) inhibitors (e.g., everolimus, ridaforolimus, and temsirolimus), and kits therefor are provided. 提供用于通过给予艾日布林(例如甲磺酸艾日布林，即E7389，Halaven)与种或多种雷帕霉素的哺乳动物靶(mTOR)抑制剂(例如依维莫司、地磷莫司和坦西莫司)的组合治疗有需要的受试者(例如人类患者)中的癌症(例如乳腺癌、肺癌、胰腺癌、原始神经外胚层肿瘤、肺癌、卵巢癌、子宫内膜癌、咽癌、食道癌和肉瘤)的方法及用于所述方法的试剂盒。